TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  The Motley Fool

Seres (MCRB) Q3 2025 Earnings Call Transcript

The Motley Fool Logo The Motley Fool By Motley Fool Transcribing
Seres (MCRB) Q3 2025 Earnings Call Transcript

Seres Therapeutics reported Q3 2025 earnings, highlighting progress on SER-155, a live biotherapeutic targeting bloodstream infections in stem cell transplant patients. The company secured a $3.6M CARB-X grant, reduced workforce by 25%, and is seeking additional capital to advance clinical trials.

Insights
GOOG   positive

Demonstrated technological leadership by achieving a breakthrough with its Willow quantum chip, running a verifiable algorithm beyond traditional supercomputer capabilities.


MCRB   neutral

Mixed financial performance with net income from a one-time sale offset by ongoing operational losses, ongoing capital constraints, and workforce reduction, but promising clinical trial progress and external grant funding